Idera Begins IMO-3100 Phase 1 Trial
In the Phase 1 trial, IMO-3100 is being administered by subcutaneous injection to healthy subjects in a rising single-dose design. The primary objective is to evaluate safety and
Bayer has announced plans to invest $2.2bn in a new pharmaceutical manufacturing facility in Ohio, US.